-
Subject Areas on Research
-
A comprehensive review of topical hemostatic agents: efficacy and recommendations for use.
-
A hemorrhage of off-label use.
-
A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting.
-
A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial).
-
Activated clotting time measurements and aprotinin studies.
-
Activation of NADPH oxidase 1 increases intracellular calcium and migration of smooth muscle cells.
-
Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.
-
Angiographic diagnosis and endovascular management of nonvariceal gastrointestinal hemorrhage.
-
Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas.
-
Antiphospholipid antibodies after surgical exposure to topical bovine thrombin.
-
Application of energy-based technologies and topical hemostatic agents in the management of surgical hemostasis.
-
Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial.
-
Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes.
-
Aprotinin versus tranexamic acid: the controversy continues.
-
Aprotinin's effect on blood product transfusion in off-pump bilateral lung transplantation.
-
Aprotinin: a pharmacologic overview.
-
Aprotinin: safe and effective only with the full-dose regimen.
-
Avoidance of primary post-tonsillectomy hemorrhage in a teaching program.
-
Bilateral pulmonary emboli associated with intraoperative use of thrombin-based hemostatic matrix following lumbar spine interbody fusion.
-
Bleeding and management of coagulopathy.
-
Blood Products in the Management of Abnormal Placentation.
-
Bovine thrombin: history, use, and risk in the surgical patient.
-
Carotid and vertebral artery sacrifice with a combination of Onyx and coils: technical note and case series.
-
Case 1-2008. One institution's decreasing use of aprotinin during cardiac surgery in 2006.
-
Case 3--1999. Intraoperative coronary thrombosis in association with low-dose aprotinin therapy.
-
Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO.
-
Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use.
-
Consensus Statement: Hemostasis Trial Outcomes in Cardiac Surgery and Mechanical Support.
-
Controlled survival study of the effects of Tisseel or a combination of FloSeal and Tisseel on major vascular injury and major collecting-system injury during partial nephrectomy in a porcine model.
-
Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial.
-
Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding.
-
Difficult-to-control bleeding.
-
Does body mass index impact the outcomes of tubeless percutaneous nephrolithotomy?
-
Effectiveness of Glycerol Mono-oleate as a Biosealant.
-
Efficacy and safety of aprotinin in cardiac surgery.
-
Emergency portacaval shunts: is Orloff correct?
-
Engineering a new generation of hemostatic agents: highlights of the Scientific Session on Hemostasis at the 2013 meeting of the American Society of Hematology.
-
Enhancement of experimental anaerobic infections by blood, hemoglobin, and hemostatic agents.
-
Evaluation and management of postpartum hemorrhage: consensus from an international expert panel.
-
Evaluation of the safety and efficacy of a new hemostatic powder using a quantitative surface bleeding severity scale.
-
Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose.
-
Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding.
-
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
-
Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations.
-
Hemostatic agents and their safety.
-
Hemostatic agents.
-
Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation.
-
Hemostatic effects of therapeutic plasma exchange: A concise review.
-
Hemostatic properties of the FVIIa analog NN1731.
-
Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction.
-
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
-
Histopathologic and immunohistochemical sequelae of bariatric embolization in a porcine model.
-
Invited commentary.
-
Maintaining Hemostatic Balance in Treating Disseminated Intravascular Coagulation.
-
Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen.
-
Management of gynecologic surgery in the patient with factor XI deficiency: a review of the literature.
-
Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH.
-
Management of surgical hemostasis: systemic agents.
-
Management of surgical hemostasis: topical agents.
-
Managing clotting: a North American perspective.
-
Massive transfusion coagulopathy.
-
Mechanisms and monitoring of bypassing agent therapy.
-
Middle ear packing: comparison of materials in an animal model of mucosal trauma.
-
Multidisciplinary approach to the challenge of hemostasis.
-
Novel delivery of oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy model.
-
Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression.
-
Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration.
-
Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation.
-
Pathologic evaluation of hemostatic agents in percutaneous nephrolithotomy tracts in a porcine model.
-
Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface.
-
Perioperative coagulation management in the intensive care unit.
-
Perioperative hemostatic management of patients treated with vitamin K antagonists.
-
Perioperative management of the bleeding patient.
-
Pharmacokinetics of methanol and formate in female cynomolgus monkeys exposed to methanol vapors.
-
Pharmacologic methods to reduce perioperative bleeding.
-
Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations.
-
Predicting and preventing adverse neurologic outcomes with cardiac surgery.
-
Product comparison model in otolaryngology: Equivalency analysis of absorbable hemostatic agents after endoscopic sinus surgery.
-
Prohemostatic agents to prevent perioperative blood loss.
-
Prohemostatic treatment in cardiac surgery.
-
Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.
-
Protocolized hemostatic factor use in major thoracic aortic surgery.
-
Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery: post hoc analysis and interpretation of phase III results.
-
Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy.
-
Rapid evaluation of coagulopathies after cardiopulmonary bypass in children using modified thromboelastography.
-
Recent clinical and investigational applications of fibrin sealant in selected surgical specialties.
-
Recent developments in topical thrombins.
-
Recombinant activated factor VII and the anaesthetist.
-
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
-
Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference.
-
Relative purity of thrombin-based hemostatic agents used in surgery.
-
Safety of aprotinin in congenital heart operations: results from a large multicenter database.
-
Safety of aprotinin in heparinized and nonheparinized patients.
-
Safety of recombinant activated factor VII in randomized clinical trials.
-
Scanning electron microscopical observations of two novel hemostatic polymers.
-
Serine 232 of the alpha(2A)-adrenergic receptor is a protein kinase C-sensitive effector coupling switch.
-
Sonographic appearance of oxidized cellulose (Surgicel): pitfall in the diagnosis of postoperative abscess.
-
Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution.
-
Sparing of Descending Axons Rescues Interneuron Plasticity in the Lumbar Cord to Allow Adaptive Learning After Thoracic Spinal Cord Injury.
-
Successful sonographically guided thrombin injection in an infant with a femoral artery pseudoaneurysm.
-
Supplementary fibrinogen in the management of bleeding: re-evaluation of data from clinical trials.
-
The Tissue Factor Pathway and Wound Healing.
-
The Use of Topical Hemostatic Agents in Cardiothoracic Surgery.
-
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
-
The anticoagulated patient: strategies for effective blood loss management.
-
The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2.
-
The role of aprotinin in a blood-conservation program.
-
Tissue factor-activated thromboelastograms in children undergoing cardiac surgery: baseline values and comparisons.
-
Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).
-
Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of US-guided thrombin injection with compression repair.
-
USE OF TANNED COLLAGEN SPONGES IN THE TREATMENT OF LIVER INJURIES.
-
Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization.
-
Update on hemostasis: neurosurgery.
-
Use of 1-desamino-8-D-arginine vasopressin in microsurgical reconstruction in a patient with von Willebrand's disease.
-
Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH.
-
Use of fibrin sealant as a hemostatic agent after liver biopsy in swine.
-
Use of human fibrinogen concentrate during proximal aortic reconstruction with deep hypothermic circulatory arrest.
-
Use of the Outreach Distal Access Catheter for microcatheter stabilization during intracranial arteriovenous malformation embolization.
-
Vessel occlusion with transcatheter electrocoagulation: initial clinical experience.
-
Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel.
-
Women and girls with haemophilia: Lessons learned.
-
von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
-
von Willebrand disease in the 21st century: current approaches and new challenges.
-
Keywords of People